Breaking Finance News

A statement released earlier today by Oppenheimer Holdings Inc. about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) bumps the target price to $55.00

Oppenheimer Holdings Inc. bumped up the target price of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to $55.00 stating a potential upside of 0.08%.

On 10/12/2015, Leerink Partners released a statement for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) bumped up the target price from $67.00 to $71.00 that suggested an upside of 0%.

Displaying a price of $50.89, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) traded 1.49% higher on the day. With the last close up 6.04% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.03% over the date range. Neurocrine Biosciences, Inc. has recorded a 50-day average of $46.81 and a two hundred day average of $48.15. Volume of trade was down over the average, with 326,115 shares of NBIX changing hands under the typical 857,864

Performance Chart

Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

With a total market value of $0, Neurocrine Biosciences, Inc. has with a one year low of $31.25 and a one year high of $57.82 .

A total of 8 firms have reported on the stock. 3 brokerages rating the stock a strong buy, 6 brokers rating the stock a buy, 0 brokers rating the stock a hold, zero analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $68.25.

Brief Synopsis About Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company's two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women's health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Company focuses on developing NBI-640756 against Essential tremor. Its research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases. Its Corticotropin-Releasing Factor (CRF) is a hypothalamic hormone released directly into the hypophyseal portal vasculature.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *